C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Core Viewpoint - C4 Therapeutics, Inc. (CCCC) has experienced a significant decline of 23.1% over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1][5][6]. Group 1: Stock Performance and Indicators - The stock has faced excessive selling pressure, leading to a decline of 23.1% in the last month [1]. - CCCC's Relative Strength Index (RSI) is currently at 21.84, indicating that the heavy selling may be exhausting itself, which could lead to a price rebound [5]. - A stock is generally considered oversold when its RSI falls below 30, and CCCC's current RSI suggests it is approaching this threshold [2][3]. Group 2: Earnings Estimates and Analyst Consensus - Over the past 30 days, the consensus EPS estimate for CCCC has increased by 0.3%, indicating a positive trend in earnings revisions [6]. - There is strong agreement among sell-side analysts regarding the potential for CCCC to report better earnings, which typically correlates with price appreciation [6]. - CCCC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].